Cytokinetics, Inc. : Amgen and Cytokinetics Announce Expansion of License for Omecamtiv Mecarbil

Cytokinetics, Inc. : Amgen and Cytokinetics Announce Expansion of License for
                              Omecamtiv Mecarbil

Cytokinetics Will Receive  $25 Million Plus  Potential Milestone Payments  and 

THOUSAND OAKS, Calif. AND SOUTH SAN FRANCISCO, Calif, (June 12, 2013) -  Amgen 
(NASDAQ:AMGN) and Cytokinetics Incorporated  (NASDAQ:CYTK) today announced  an 
expansion of  their  strategic  collaboration  to  include  Japan.  In  2006, 
Cytokinetics and Amgen entered into  a collaboration to discover, develop  and 
commercialize novel small-molecule therapeutics  that activate cardiac  muscle 
contractility for potential  applications in the  treatment of heart  failure. 
Omecamtiv mecarbil is the most advanced drug candidate in this collaboration.
Initially, Cytokinetics'  license to  Amgen for  omecamtiv mecarbil  excluded 
Japan.  Under  the  amendment  to  the  collaboration  announced  today,  the 
companies have  agreed  on  terms  expanding  Amgen's  license  for  omecamtiv 
mecarbil and related compounds to include Japan.

In consideration  of  the  expanded license,  Cytokinetics  will  receive  $25 
million from Amgen comprised  of a non-refundable license  fee of $15  million 
and $10  million for  Amgen's  purchase of  Cytokinetics' common  stock.  The 
companies have executed a stock purchase  agreement providing for the sale  of 
Cytokinetics' common stock to Amgen at a  price per share equal to the  10-day 
trailing average  of the  closing price  of Cytokinetics'  stock on  the  last 
trading day prior to execution of the stock purchase agreement. In  addition, 
Cytokinetics is eligible to receive additional pre-commercialization milestone
payments for  the development  of omecamtiv  mecarbil in  Japan of  up to  $50 
million as well as royalties on  sales of omecamtiv mecarbil in Japan.  Under 
the terms  of  the  amended collaboration  agreement,  Cytokinetics  plans  to 
conduct a Phase I pharmacokinetic study, the costs of which will be reimbursed
by Amgen,  intended  to  support  the inclusion  of  Japanese  patients  in  a 
potential Phase III clinical development program for omecamtiv mecarbil. 

"We are pleased  to expand  our collaboration  with Amgen  to include  Japan," 
stated Robert I.  Blum, Cytokinetics' President  and Chief Executive  Officer. 
"Our decision to amend the agreement at this time is based on our  confidence 
in the  progress  of  our  collaborative  development  program  for  omecamtiv 
mecarbil and on Amgen's recent commitment to expand its business activities in
Japan. We look forward  to the integration of  Japan into our  collaboration's 
global development plan for this promising drug candidate." 

"This expanded  collaboration  furthers  Amgen's hopes  to  address  needs  of 
patients with heart  failure in  Japan," said  Sean E.  Harper, M.D.,  Amgen's 
Executive Vice President of Research and Development.

About Omecamtiv Mecarbil
Omecamtiv mecarbil  is a  small molecule  cardiac myosin  activator which  was 
discovered by Cytokinetics' scientists and  is the subject of a  collaboration 
between Cytokinetics and Amgen. It is being investigated for the treatment of
heart failure.

About Amgen
Amgen  discovers,  develops,  manufactures   and  delivers  innovative   human 
therapeutics. A biotechnology pioneer since 1980,  Amgen was one of the  first 
companies to realize  the new  science's promise by  bringing safe,  effective 
medicines from lab to manufacturing plant to patient. Amgen therapeutics  have 
changed the practice of medicine, helping people around the world in the fight
against serious illnesses.  With a deep  and broad pipeline  of potential  new 
medicines, Amgen  remains  committed  to  advancing  science  to  dramatically 
improve people's lives. For more  information, visit and  follow 
us on

About Cytokinetics
Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function  for the  potential treatment  of serious  diseases and  other 
medical conditions. Cytokinetics  currently has three  compounds in  clinical 
development: omecamtiv  mecarbil  in Phase  II  for acute  and  chronic  heart 
failure,  tirasemtiv  in  Phase  II  for  amyotrophic  lateral  sclerosis  and 
CK-212107 in a Phase I study in healthy volunteers. All of the company's  drug 
candidates have  arisen from  Cytokinetics'  muscle biology  focused  research 
activities and are directed  towards the cytoskeleton.  The cytoskeleton is  a 
complex biological infrastructure that plays  a fundamental role within  every 
human cell.  Additional information  about Cytokinetics  can be  obtained  at

Forward-Looking Statements: Amgen
This news release contains forward-looking statements that involve significant
risks and uncertainties, including those  discussed below and others that  can 
be found in Amgen's Form 10-K for the year ended December 31, 2012, and in any
subsequent periodic reports  on Form 10-Q  and Form 8-K.  Amgen is  providing 
this information as of the  date of this news  release and does not  undertake 
any obligation  to update  any forward-looking  statements contained  in  this 
document as a result of new information, future events or otherwise.

No forward-looking statement can be  guaranteed and actual results may  differ 
materially from  those Amgen  projects. Amgen's  results may  be affected  by 
Amgen's  ability  to  successfully  market  both  new  and  existing  products 
domestically  and  internationally,   clinical  and  regulatory   developments 
(domestic or foreign) involving current  and future products, sales growth  of 
recently launched  products,  competition  from other  products  (domestic  or 
foreign) and  difficulties  or  delays  in  manufacturing  its  products.  In 
addition, sales  of  Amgen products  are  affected by  reimbursement  policies 
imposed by third-party payers, including governments, private insurance  plans 
and managed care  providers and may  be affected by  regulatory, clinical  and 
guideline developments and  domestic and international  trends toward  managed 
care and healthcare  cost containment  as well as  U.S. legislation  affecting 
pharmaceutical pricing and reimbursement. Government and others'  regulations 
and reimbursement policies may  affect the development,  usage and pricing  of 
Amgen products. Furthermore,  Amgen's research,  testing, pricing,  marketing 
and other  operations are  subject  to extensive  regulation by  domestic  and 
foreign government  regulatory authorities.  Amgen or  others could  identify 
safety, side effects or manufacturing problems with Amgen products after  they 
are  on  the  market.  Amgen's   business  may  be  impacted  by   government 
investigations, litigation and  product liability claims.  If Amgen fails  to 
meet the compliance obligations in  the corporate integrity agreement  between 
Amgen and  the U.S.  government,  Amgen could  become subject  to  significant 
sanctions. Further, while  Amgen routinely obtains  patents for its  products 
and technology, the protection offered by its patents and patent  applications 
may be  challenged, invalidated  or circumvented  by its  competitors.  Amgen 
depends on  third  parties for  a  significant portion  of  its  manufacturing 
capacity for the  supply of  certain of its  current and  future products  and 
limits on supply may  constrain sales of certain  of its current products  and 
product  candidate  development.  In  addition,  Amgen  competes  with  other 
companies with respect to  some of its  marketed products as  well as for  the 
discovery and development of new products. Discovery or identification of new
product candidates cannot be guaranteed  and movement from concept to  product 
is uncertain;  consequently, there  can be  no guarantee  that any  particular 
product  candidate  will  be  successful  and  become  a  commercial  product. 
Further, some raw materials,  medical devices and  component parts for  Amgen 
products  are  supplied  by  sole  third-party  suppliers.  Amgen's   business 
performance could affect  or limit the  ability of its  Board of Directors  to 
declare a dividend or its ability to  pay a dividend or repurchase its  common 

Forward-Looking Statements: Cytokinetics
This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  Safe  Harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating  to Cytokinetics'  and  Amgen's research  and  development 
activities, including the  planned conduct of  clinical trials; the  potential 
receipt of milestones, royalties  and other payments;  and the properties  and 
potential  benefits  of  omecamtiv  mecarbil  and  Cytokinetics'  other   drug 
candidates. Such statements  are based on  management's current  expectations, 
but  actual  results  may   differ  materially  due   to  various  risks   and 
uncertainties, including, but not limited to: Cytokinetics anticipates that it
will be required to conduct at least one confirmatory Phase III clinical trial
of tirasemtiv  in  ALS  patients which  will  require  significant  additional 
funding, and it may be unable to obtain such additional funding on  acceptable 
terms, if  at  all;  potential  difficulties or  delays  in  the  development, 
testing, regulatory approvals for  trial commencement, progression or  product 
sale or manufacturing,  or production  of Cytokinetics'  drug candidates  that 
could slow  or prevent  clinical development  or product  approval,  including 
risks that current and past results of clinical trials or preclinical  studies 
may not be indicative  of future clinical  trials results, patient  enrollment 
for or conduct of clinical trials  may be difficult or delayed,  Cytokinetics' 
drug candidates  may  have  adverse side  effects  or  inadequate  therapeutic 
efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies
may delay or limit Cytokinetics' or its partners' ability to conduct  clinical 
trials, and Cytokinetics may be unable  to obtain or maintain patent or  trade 
secret protection  for  its  intellectual  property;  Amgen's  decisions  with 
respect to  the  design,  initiation,  conduct,  timing  and  continuation  of 
development  activities  for  omecamtiv   mecarbil;  Cytokinetics  may   incur 
unanticipated research and development and other costs or be unable to  obtain 
additional  financing  necessary  to  conduct  development  of  its  products; 
Cytokinetics may be unable to  enter into future collaboration agreements  for 
its drug candidates and programs on acceptable terms, if at all; standards  of 
care may change, rendering Cytokinetics' drug candidates obsolete; competitive
products or alternative therapies may be developed by others for the treatment
of indications Cytokinetics' drug candidates and potential drug candidates may
target; and risks  and uncertainties  relating to  the timing  and receipt  of 
payments from  its  partners, including  milestones  and royalties  on  future 
potential product sales under Cytokinetics' collaboration agreements with such
partners. For further information regarding  these and other risks related  to 
Cytokinetics' business, investors  should consult  Cytokinetics' filings  with 
the Securities and Exchange Commission.

Kristen Davis, 805-447-3008 (Amgen media)
Arvind Sood, 805-447-1060 (Amgen investors)
Joanna L. Goldstein, 650-624-3000 (Cytokinetics investors & media)


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.